SCOPUS 정보 검색 플랫폼

Medecine et Maladies Infectieuses

Volumn 38, Issue SUPPL. 1, 2008, Pages 12-16

Clinical pharmacokinetic of maraviroc;Pharmacocinétique clinique du maraviroc

(1) Peytavin, G a

a BICHAT HOSPITAL (France)

Author keywords

CCR5 antagonists; Maraviroc; Pharmacokinetic; PK PD relationship

Indexed keywords

ANTIRETROVIRUS AGENT; CARBAMAZEPINE; CLARITHROMYCIN; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DELAVIRDINE; EFAVIRENZ; ENFUVIRTIDE; ITRACONAZOLE; KETOCONAZOLE; MARAVIROC; NEFAZODONE; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; RITONAVIR; TELITHROMYCIN; TIPRANAVIR;

ARTICLE; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

EID: 44049085759 PISSN: 0399077X EISSN: 17696690 Source Type: Journal
DOI: 10.1016/S0399-077X(08)70539-0 Document Type: Article

Times cited : (3)

References (24)

1
- 15344350690
- Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV
- D.K. Walker S. Abel P. Comby G.J. Muirhead A.N.R. Nedderman D.A. Smith Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV Drug Metab Dispo 33 2005 587 595
- (2005) Drug Metab Dispo , vol.33 , pp. 587-595
- Walker, D.K.¹ Abel, S.² Comby, P.³ Muirhead, G.J.⁴ Nedderman, A.N.R.⁵ Smith, D.A.⁶

2
- 0037356428
- Gateways to clinical trials
- M. Bayés X. Rabasseda J.R. Prous Gateways to clinical trials Methods Find Exp Clin Pharmacol 25 2003 145 168
- (2003) Methods Find Exp Clin Pharmacol , vol.25 , pp. 145-168
- Bayés, M.¹ Rabasseda, X.² Prous, J.R.³

3
- 30744447460
- Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
- G. Fätkenheuer A.L. Pozniak M.A. Johnson A. Plettenberg S. Staszewski A.I.M. Hoepelman Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 Nature Med 11 2005 1170 1172
- (2005) Nature Med , vol.11 , pp. 1170-1172
- Fätkenheuer, G.¹ Pozniak, A.L.² Johnson, M.A.³ Plettenberg, A.⁴ Staszewski, S.⁵ Hoepelman, A.I.M.⁶

4
- 27744548649
- The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS
- A. Wood D. Armour The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS Progr Medicin Chem 43 2005 239 271
- (2005) Progr Medicin Chem , vol.43 , pp. 239-271
- Wood, A.¹ Armour, D.²

5
- 27644510382
- Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broadspectrum anti-human immunodeficiency virus type 1 activity
- P. Dorr M. Westby S. Dobbs P. Griffin B. Irvine M. Macartney Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broadspectrum anti-human immunodeficiency virus type 1 activity Anti-microb Agents Chemother 49 2005 4721 4732
- (2005) Anti-microb Agents Chemother , vol.49 , pp. 4721-4732
- Dorr, P.¹ Westby, M.² Dobbs, S.³ Griffin, P.⁴ Irvine, B.⁵ Macartney, M.⁶

6
- 85119731430
- Investigation of the pharmacokinetics of maraviroc following IV dosing, and determination of absolute bioavailability following 100 mg oral dosing [abstract]
- th International Workshop on Clinical Pharmacology of HIV Therapy Lisbonne, Portugal, avril 2006 2006 Abstract 59A
- (2006)
- Abel, S.¹ Russell, D.² Whitlock, L.³ Ridgway, C.⁴ Weissgerber, G.⁵

7
- 85119772744
- Investigation of the population pharmacokinetics of maraviroc following IV dosing [abstract]
- th International Workshop on Clinical Pharmacology of HIV Therapy 2006 Abstract 59B
- (2006)
- Weatherley, B.¹ McFadyen, L.² Abel, S.³

8
- 85119766667
- Population pharmacokinetics of phase 1/2a data after oral tablet administration of maraviroc – a novel residual error model [abstract]
- th International Workshop on Clinical Pharmacology of HIV Therapy 2007 Abstract 16
- (2007)
- Chan, P.L.S.¹ Weatherley, B.² McFadyen, L.³

9
- 85119740586
- An open, parallel group study to compare the pharmacokinetics, safety and toleration of a single oral dose of maraviroc in subjects with mild and moderate hepatic impairment with subjects with normal hepatic function [abstract]
- th International Workshop on Clinical Pharmacology of HIV Therapy Budapest, Hongrie. avril 2007 2007 Abstract 8
- (2007)
- Abel, S.¹ Ridgway, C.² Hamlin, J.³ Davis, J.⁴

10
- 85119758508
- The effect of P450 inducers on the pharmacokinetics of CCR5 antagonist, UK-427,857, in healthy volunteers [abstract]
- th International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italie, avril 2004 2004 Abstract 5.4
- (2004)
- Jenkins, T.¹ Abel, S.² Russell, D.³ Boucher, M.⁴ Whitlock, L.⁵ Weissgerber, G.⁶

11
- 85119760627
- Effect of CCR5 antagonist UK-427,857 on the pharmacokinetics of CYP3A4 substrates in healthy volunteers [abstract]
- th International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italie, avril 2004 2004 Abstract 5.7
- (2004)
- Abel, S.¹ Russell, D.² Ridgway, C.³ Medhurst, C.⁴ Whitlock, L.⁵ Weissgerber, G.⁶

12
- 85119760155
- Effect of CYP3A4 inhibitors on the pharmacokinetics of CCR5 antagonist UK-427,857 in healthy volunteers [abstract]
- th International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italie, avril 2004 2004 Abstract 5.8
- (2004)
- Abel, S.¹ Russell, D.² Ridgway, C.³ Medhurst, C.⁴ Weissgerber, G.⁵ Muirhead, G.⁶

13
- 84884911365
- An investigation of the effects of atazanavir and ritonavir boosted atazanavir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857 [abstract]
- th International Congress on Drug Therapy in HIV infection Glasgow, Royaume Uni, novembre 2004 2004 Abstract P283
- (2004)
- Muirhead, G.¹ Abel, S.² Russell, D.³ Hackman, F.⁴ Taylor-Worth, R.⁵ Toh, M.⁶

14
- 85119765173
- A study to investigate the combined co-administration of P450 CYP3A4 inhibitors and inducers on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857 [abstract]
- th International Congress on Drug Therapy in HIV infection Glasgow, Royaume Uni, novembre 2004 2004 Abstract P284
- (2004)
- Russell, D.¹ Ridgway, C.² Mills, C.³ van der Merwe, R.⁴ Muirhead, G.⁵

15
- 85119782039
- Overview of the drug-drug interaction data for maraviroc (UK-427,857) [abstract]
- th International Workshop on Clinical Pharmacology of HIV Therapy Québec, Canada, avril 2005 2005 Abstract 76
- (2005)
- Abel, S.¹ Russell, D.² Ridgway, C.³ Muirhead, G.⁴

16
- 29744462285
- A novel probe drug interaction study to investigate the effect of selected ARV combinations on the PK of a single oral dose of maraviroc in HIV positive subjects [abstract]
- th International Workshop on Clinical Pharmacology of HIV Therapy Québec, Canada, avril 2005 2005 Abstract 31
- (2005)
- Muirhead, G.¹ Russell, D.² Pozniak, A.³ Boffito, M.⁴ Moyle, G.J.⁵ Gazzard, B.⁶

17
- 85119766108
- Effect of boosted tipranavir on the pharmacokinetics of maraviroc (UK-427, 857) in healthy volunteers [abstract]
- th European AIDS Conference Dublin, Irlande, novembre 2005 2005 Abstract LBPE4.3/15
- (2005)
- Abel, S.¹ Taylor-Worth, R.² Ridgway, C.³ Weissgerber, G.⁴ Kraft, M.⁵

18
- 85119766108
- Effect of boosted tipranavir on the pharmacokinetics of maraviroc (UK427,857) in healthy volunteers [abstract]
- th International Workshop on Clinical Pharmacology of HIV Therapy Lisbonne, Portugal, avril 2006 2006 Abstract 77
- (2006)
- Abel, S.¹ Taylor-Worth, R.² Ridgway, C.³ Weissgerber, G.⁴ Kraft, M.⁵

19
- 84884915901
- An open, randomized, 2-way crossover study to investigate the effect of darunavir/ritonavir on the pharmacokinetics of maraviroc in healthy subjects [abstract]
- th International Workshop on Clinical Pharmacology of HIV Therapy Budapest, Hongrie, avril 2007 2007 Abstract 55
- (2007)
- Abel, S.¹ Ridgway, C.² Hamlin, J.³ Davis, J.⁴ Mack, R.⁵ Sekar, V.⁶

20
- 85119776595
- Impact of concomitant interacting drugs on maraviroc pharmacokinetics after oral tablet administration [abstract]
- th International Workshop on Clinical Pharmacology of HIV Therapy Budapest, Hongrie, avril 2007 2007 Abstract 65
- (2007)
- Chan, P.L.S.¹ Weatherley, B.² McFadyen, L.³ Abel, S.⁴

21
- 85119782173
- ®.

22
- 84884911365
- An investigation of the effects of tenofovir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857 [abstract]
- th International Congress on Drug Therapy in HIV infection Glasgow, Royaume Uni, novembre 2004 2004 Abstract P282
- (2004)
- Muirhead, G.¹ Russell, D.² Abel, S.³ Turner, K.⁴ Taylor-Worth, R.⁵ Tan, L.H.⁶

23
- 85119767508
- The effect of maraviroc (UK-427,857) on the pharmacokinetics of 3TC/AZT (Combivir) in healthy subjects [abstract]
- th International Workshop on Clinical Pharmacology of HIV Therapy Québec, Canada, avril 2005 2005 Abstract 30
- (2005)
- Russell, D.¹ Abel, S.² Hackman, F.³ Whitlock, L.⁴ Van der Merwe, R.⁵ Muirhead, G.⁶

24
- 33745077340
- A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc
- M.C. Rosario B. Poland J. Sullivan M. Westby E. van der Ryst A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc J Acquir Immune Defic Syndr 42 2006 183 191
- (2006) J Acquir Immune Defic Syndr , vol.42 , pp. 183-191
- Rosario, M.C.¹ Poland, B.² Sullivan, J.³ Westby, M.⁴ van der Ryst, E.⁵

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.